Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Product: Tadomon
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Tadomon 50mg prolonged-release tablets
0407020AGBDAAAC
|
Tadomon | Tapentadol | Central Nervous System | 14 |
|
Tadomon 150mg prolonged-release tablets
0407020AGBDACAE
|
Tadomon | Tapentadol | Central Nervous System | 6 |
|
Tadomon 100mg prolonged-release tablets
0407020AGBDABAD
|
Tadomon | Tapentadol | Central Nervous System | 3 |
|
Tadomon 200mg prolonged-release tablets
0407020AGBDADAF
|
Tadomon | Tapentadol | Central Nervous System | 1 |
|
Tadomon 25mg prolonged-release tablets
0407020AGBDAFAI
|
Tadomon | Tapentadol | Central Nervous System | 1 |
|
Tadomon 250mg prolonged-release tablets
0407020AGBDAEAG
|
Tadomon | Tapentadol | Central Nervous System | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.